Articles tagged with Prostate Cancer
A new test measuring multiple parameters including PSA and six antibodies found in the blood of men with prostate cancer is more sensitive and specific than the conventional PSA test. The A+PSA assay reduces false-positives and shows great potential to improve prostate cancer diagnosis.
Men who are overweight or obese face a three-fold increased risk of cancer progression and more than a three-fold increased risk of metastases compared to normal-weight men. Obesity is linked to poorer outcomes in prostate cancer patients, regardless of treatment.
Researchers at Mayo Clinic found that patients diagnosed with advanced prostate cancer can enjoy long-term survival and a significant cancer-free interval. The study showed an 80% survival rate for patients with locally advanced prostate cancer at 20 years after surgery.
A new technology fusion of MRI with real-time 3D ultrasound improves targeted biopsy accuracy for prostate cancer diagnosis. The system identifies suspicious areas in the prostate and provides a roadmap for biopsy needle guidance, increasing cancer detection rates by five times compared to conventional biopsies.
Researchers find increased MAN2C1 levels enhance prostate cancer recurrence and metastasis, highlighting a potential target for blocking tumor progression. The study could lead to the development of new treatments for patients with advanced prostate cancer.
Researchers combine Sabutoclax with viral gene therapy to prevent tumor growth in prostate-cancer-prone mice, offering a novel approach to treating advanced prostate cancer. The study's findings suggest that this combination therapy could be effective in other cancers and pave the way for personalized medicine.
Scientists selectively sensitized prostate cancer cells to radiation therapy by knocking down a key protein repair gene. The approach shows promise for treating locally advanced prostate cancer, reducing disease recurrence.
A new biomarker for diagnosing prostate cancer has been found to be more reliable than current methods, reducing false positives and unnecessary operations. The study, published in PNAS, uses a unique test that detects elevated levels of prostasomes in blood, which are released by cancer cells into the surrounding tissue.
A Swedish research team found that surgery significantly reduces prostate cancer mortality risk, even among men with low-risk tumours. The study followed 347 patients and found that surgical patients had a lower risk of dying from prostate cancer than those who underwent watchful waiting.
A recent study published at the American Radium Society Annual Meeting found that aspirin use lowers the risk of cancer recurrence in prostate cancer patients who have received radiotherapy. After 10 years, men taking aspirin had a 31% lower rate of biochemical failure compared to non-aspirin users.
Researchers at Georgetown University Medical Center report that a drug developed to treat Ewing's Sarcoma may also prevent human prostate cancer from spreading. The agent, YK-4 279, was found to inhibit functions of proteins responsible for aggressive cell behavior in prostate cancer cells.
Researchers found that tissue spacers significantly reduced the rectal dose administered to patients receiving radiation therapy for prostate cancer. This led to minimal damage to the rectum, enabling radiation oncologists to increase treatment doses without concern.
Scripps Research and Moffitt Cancer Center collaborate on a $2.1 million grant to understand the origins of prostate cancer and develop novel treatments. The study aims to define how B cells control the spread of hormone-refractory cancer, potentially leading to effective treatments.
A nationwide study found that men with high levels of omega-3 fatty acids in their blood have a two-and-a-half times higher risk of developing aggressive prostate cancer. In contrast, those with high levels of trans-fatty acids had a 50% lower risk of high-grade prostate cancer.
A new study published in The Journal of Urology found that testosterone therapy does not cause rapid growth of prostate cancer in men with untreated or low-risk prostate cancer. Testosterone treatment was associated with improved symptoms and quality of life, without increasing the risk of cancer progression.
Thomas Jefferson University researchers show intensity-modulated radiotherapy (IMRT) delivers higher doses to the prostate bed while sparing surrounding tissue, leading to improved PSA levels and reduced side effects. The study fills a gap in documentation of this technique's benefits for post-operative patients.
A large-scale study of 769 men with low-grade prostate cancer found that closely monitoring the disease without immediate treatment does not raise the risk of death. Men who undergo active surveillance are less likely to need subsequent surgery or radiation if their cancer progression is carefully monitored.
A new PSA test has been shown to detect aggressive prostate cancer more accurately than current tests and reduce unnecessary biopsies. The Pro-PSA test uses a specific PSA subform called (-2) Pro-PSA and can be analyzed with a mathematical formula to provide an overall Prostate Health Index.
Researchers at Fox Chase Cancer Center have discovered two novel genetic markers associated with earlier time to prostate cancer diagnosis among African American men. Genetic variations in miRNA binding sites, particularly in genes IL-16 and IL-18, were found to increase the risk of early diagnosis.
U-M scientists identified a genetic anomaly in the KRAS gene, known for its role in numerous cancers, that may promote tumor progression in a rare subset of prostate cancers. This finding suggests different subtypes of prostate cancer will need targeted treatment strategies.
A multidisciplinary team identified digoxin as a possible therapy for prostate cancer through drug repositioning. Regular digoxin use reduced the risk of prostate cancer by 24% and 46% for long-term users, respectively.
Researchers have identified an oncogenic gene fusion of KRAS in a metastatic prostate cancer cell line, shedding light on the genetic characteristics of this disease. This finding may enable better prognostic information to separate slow-growing tumors from aggressive ones, ultimately improving treatment strategies.
Researchers found that men using digoxin had a 24% lower risk of prostate cancer. The study also identified other approved drugs with anti-prostate cancer properties, paving the way for further research and potential new treatments.
Researchers have found a new method for detecting prostate cancer that analyzes non-tumor tissue, potentially improving diagnosis accuracy. This approach could help reduce the number of repeat biopsies and improve patient outcomes.
A new study found that nearly half of elderly men in their seventies underwent PSA screening, while those aged 85 and older screened just as often as those in their early fifties. The high rate of unnecessary screenings may lead to complications such as incontinence and impotence.
A new study found that combining 6 months of hormone therapy with radiotherapy significantly improved survival rates for men with locally advanced prostate cancer. The treatment reduced the risk of death from prostate cancer by half and deaths from any cause by a third compared to radiation alone.
A study of over 3,000 patients found robot-assisted prostate surgery to be safe, with a low major complication rate and no disease recurrence after five years for nearly 87 percent of patients. The study analyzed surgical outcomes from 2005 to 2009 and addressed the lack of standardized reporting in previous literature.
Research from Brigham and Women's Hospital shows rapid adoption of newer, more expensive prostate cancer treatments between 2002-2005 without proof of cost-effectiveness. This trend is reflected in increased Medicare spending on these treatment options, which rose nearly $350 million in 2005.
A new study published in Medical Care found that hospitals with robotic technology are more likely to perform radical prostatectomy surgeries. This is the first study to investigate the impact of surgical robot acquisition on surgery rates, and it concludes that technological adoption leads to increased surgical volume.
A UCLA research team has developed a device using Velcro-like nanoscale technology to efficiently identify and capture circulating tumor cells, or CTCs, in blood samples. The new approach captures a greater number of CTCs than existing methods and could enable early detection and diagnosis of cancer.
Scientists have identified a potential target to treat an aggressive type of prostate cancer, known as SPINK1. A 'blocking' antibody to SPINK1 reduced tumor growth by up to 74% in mice. The study suggests that targeting SPINK1 may be effective in treating SPINK1-positive tumors.
A phase 3 study shows that denosumab delays and prevents bone events in men with castration-resistant prostate cancer, improving outcomes compared to zoledronic acid. Denosumab reduces the risk of bone fractures and other complications by inhibiting osteoclast activity.
Research suggests that PSA velocity is a poor predictor of prostate cancer and can lead to unnecessary biopsies. The study found that men with rapid rises in PSA levels did not have cancer more often than those with slower rises, highlighting the need for alternative screening methods.
Researchers found that PSA velocity is a poor predictor of prostate cancer and may lead to unnecessary biopsies. The study, which analyzed data from over 5,000 men, suggests that using changes in PSA levels as a basis for recommending biopsy can result in many unnecessary procedures.
New studies reveal a low initial PSA score of 3.0 ng/ml is an appropriate minimum cut-off level for biopsy targeting those at risk, while proficiency in robotic-assisted prostate surgery requires over 1,600 surgeries to master. Dutasteride may also slow early-stage prostate cancer growth.
A French study found that men who start losing hair at age 20 are twice as likely to develop prostate cancer compared to healthy men. The study also suggested that balding may be a potential risk factor for prostate cancer.
The study reveals several new prostate cancer genes, including those disrupting tumor suppressor proteins and rearrangements that create new genes. These findings may provide insights into the disease's development and suggest potential diagnostic markers and new treatments for aggressive forms of prostate cancer.
Whole genome sequencing reveals new genes tied to prostate cancer growth, including those disrupting tumor suppressors and heat shock proteins. The study identifies genomic rearrangements that may be driving cancer development and suggests a link between gene activity and DNA rearrangement.
Researchers found that dutasteride is impractical due to high costs and marginal impact on survival and quality of life for at-risk groups. The medication's annual cost of $1,400 outweighs its benefits, making it less effective as a preventive measure.
A four-gene signature has been identified as a reliable predictor of metastatic prostate cancer, outperforming traditional methods in accuracy. The discovery could lead to the development of gene-based tests for determining prostate cancer's potential to spread.
Researchers found a protein called FUS that inhibits prostate cancer cell growth and activates pathways leading to cell suicide. Higher levels of FUS correlate with less aggressive cancer and longer survival.
A research project aims to analyze the genomes of 250 prostate cancer patients under 50 to identify genetic mutations that cause and promote the disease. The goal is to produce a comprehensive map of genetic modifications involved in prostate cancer, which may lead to new treatment approaches and diagnostic methods.
Researchers at UT MD Anderson Cancer Center found that a specific microRNA, miR-34a, suppresses prostate cancer stem cells and metastasis by targeting the surface protein CD44. The study provides a strong rationale for developing new treatment options for prostate cancer.
A recent study published in the Journal of Biological Chemistry reveals that PSA (prostate-specific antigen) levels correlate with prostate cancer progression due to a complex formed between PSA and cell surface receptor GRP78. This binding stimulates pathways promoting tumor growth, cell movement, and blocking apoptosis.
Researchers discovered that SIRT1 inhibits prostatic intraepithelial neoplasia (PIN), a precursor to prostate cancer, by promoting autophagy. The study suggests that activating SIRT1 could block prostate cancer and promote longevity.
A Swedish study found that PSA screening nearly halves prostate cancer mortality after 14 years. However, the screening was associated with a risk of impotence and urinary incontinence, albeit at lower rates than expected.
A national survey found that 76% of people would take a predictive test to learn about their future health risks, with willingness to pay varying by disease type and accuracy. Respondents were more likely to pay for tests related to breast and prostate cancer, and were willing to alter lifestyle choices after receiving positive results.
A new study found that physical activity is associated with a lower risk of overall mortality and prostate cancer-specific mortality in men with prostate cancer. Men who did more vigorous activity had the lowest risk of dying from the disease.
A new UCSF study reveals that older men with high-risk prostate cancer are frequently under-treated, leading to higher mortality rates. The researchers argue that age should not be a barrier to more aggressive treatments that could lead to potential cures.
A new study published in Retrovirology reveals that cell samples used in previous research were contaminated with XMRV, not the cause of chronic fatigue syndrome. The researchers developed improved methods to detect XMRV and rule out infection by this virus as a cause of the disease.
Researchers found that a slight rise in PSA levels among men taking dutasteride was a stronger indicator of prostate cancer than rising PSA levels in men on a placebo. The study suggests that the drug enhances the ability to detect high-grade cancers, making the PSA test more effective for early diagnosis and treatment.
Scientists from deCODE genetics and academic colleagues report discovering genetic markers that impact individual baseline levels of prostate-specific antigen (PSA). Analyzing four SNPs in tandem with genetic risk factors detected by the deCODE ProstateCancer test yields substantial improvement in PSA screening efficacy.
Researchers identified pomegranate juice components that inhibit the movement of cancer cells and weaken their attraction to a chemical signal. The effects of these components on prostate cancer progression are still controversial and require further testing.
A study found that decreased physician reimbursement for hormone therapy reduced its use in low-risk prostate cancer cases by 40%. However, AST usage remained unchanged in patients with metastatic disease. The decrease is attributed to the real effect of reimbursement change.
Researchers have identified genetic mutations associated with elevated PSA levels in men diagnosed with prostate cancer, offering potential new biomarkers for disease monitoring. The study's findings suggest that sequencing of selected mitochondrial regions could provide valuable information for prognosis.
Researchers at UCLA found that the protein Bmi-1 plays a crucial role in regulating self-renewal of normal prostate stem cells and transforming healthy cells into prostate cancer cells. Inhibiting Bmi-1 slowed the growth of aggressive prostate cancer in animal models.
A new technology uses metabolic imaging to rapidly assess prostate tumor presence and aggressiveness in real-time. The initial results validate preclinical research linking tumor metabolism speed to growth aggressiveness.
Men with longer index fingers are at a lower risk of developing prostate cancer, while those with shorter index fingers are more likely to be diagnosed. The study found that men aged under 60 were 87% less likely to have prostate cancer if their index finger was longer than their ring finger.
Active surveillance outperforms initial treatment for low-risk prostate cancer, providing a higher quality-adjusted life expectancy (QALE) and reducing adverse effects of treatment. The optimal strategy depends on individual patient preferences for surveillance or treatment.
A recent study published in Cancer found that clinical stage does not predict recurrence risk for patients with localized prostate cancer after having their prostate removed. Despite frequent errors in assigning stage, there was no association between clinical stage and prostate cancer recurrence.